Novartis Ag NVS
NYSE NVS
$143.76 +0.64 (+0.45%)
At close: Oct 9, 2026 · 4:00 PM EDT

Novartis Ag (NVS) Net Income towards Common Stockholders (2009 - 2026)

Updated

Novartis Ag (NVS) recorded Net Income towards Common Stockholders of $3.26 billion in Q2 2026, down 19.1% from $4.02 billion a year earlier but up 3.2% from the prior quarter.

Analysis

Novartis Ag (NVS) Net Income towards Common Stockholders (2009 - 2026) Analysis & Trends

On a TTM basis, Novartis Ag's Net Income towards Common Stockholders came in at $12.75 billion as of Jun 30, 2026, down 6.5% year-over-year; for FY2025, it came in at $13.97 billion, up 17.0% from FY2024.

  • Annual Net Income towards Common Stockholders has a five-year compound annual growth rate of 11.6% (FY2020 to FY2025).
  • Across earlier years, Net Income towards Common Stockholders came in at $11.94 billion in FY2024 (-19.6%), $14.85 billion in FY2023 (+113.6%), $6.96 billion in FY2022 (-13.8%) and $8.07 billion in FY2021 (unchanged).
  • Quarterly Net Income towards Common Stockholders has ranged from $1.47 billion in Q4 2022 to $16.31 billion in Q4 2021 over the past five years.
  • On a year-over-year basis, Net Income towards Common Stockholders has declined for three consecutive quarters, with growth averaging 6.1% over the last eight quarters.
  • Peak year-over-year performance for Net Income towards Common Stockholders in the last five years was growth of 676.8% in Q4 2021, against a decline of 91.0% in Q4 2022 at the low end.
  • Per Business Quant, the preceding three quarters came in at $3.16 billion (Q1 2026), $2.4 billion (Q4 2025) and $3.93 billion (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Eli Lilly 1,109.58 Bn 1,078.16 Bn 19.71 Bn 7.10 Bn
2 Johnson & Johnson 630.16 Bn 548.69 Bn 17.26 Bn 5.53 Bn
3 AbbVie 488.57 Bn 461.73 Bn 12.70 Bn 3.61 Bn
4 Merck 359.15 Bn 313.58 Bn 12.21 Bn -1.34 Bn
5 Novartis Ag 274.32 Bn 238.71 Bn 11.24 Bn 3.26 Bn
6 Astrazeneca 246.73 Bn 220.50 Bn 12.86 Bn 2.51 Bn
7 Amgen 224.28 Bn 179.68 Bn 7.24 Bn 2.38 Bn
8 Gilead Sciences 187.60 Bn 161.71 Bn 6.22 Bn -10.50 Bn
9 Pfizer 161.13 Bn 108.08 Bn 10.94 Bn -248.00 Mn
10 Vertex Pharmaceuticals 129.23 Bn 101.23 Bn 2.84 Bn 1.10 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 3.26 Bn
Mar 31, 2026 3.68 Bn
Dec 31, 2025 2.26 Bn
Sep 30, 2025 6.57 Bn
Jun 30, 2025 4.04 Bn
Mar 31, 2025 3.65 Bn
Dec 31, 2024 4.19 Bn
Sep 30, 2024 6.29 Bn
Jun 30, 2024 3.25 Bn
Mar 31, 2024 2.27 Bn
Dec 31, 2023 8.48 Bn
Sep 30, 2023 1.76 Bn
Jun 30, 2023 2.32 Bn
Mar 31, 2023 2.29 Bn
Dec 31, 2022 1.47 Bn
Sep 30, 2022 1.58 Bn
Jun 30, 2022 1.69 Bn
Mar 31, 2022 2.22 Bn
Dec 31, 2021 16.31 Bn
Sep 30, 2021 2.76 Bn
API Access

Novartis Ag Net Income towards Common Stockholders API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=NVS&period=max&api_key=YOUR_API_KEY